Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis

被引:107
作者
Johnson, TN [1 ]
Tanner, MS
Taylor, CJ
Tucker, GT
机构
[1] Univ Sheffield, Royal Hallamshire Hosp, Div Clin Sci, Sect Mol Pharmacol & Pharmacogenet, Sheffield S10 2JF, S Yorkshire, England
[2] Univ Sheffield, Childrens Hosp, Div Child Hlth, Sheffield S10 2TH, S Yorkshire, England
关键词
children; coeliac disease; CYP3A4; cystic fibrosis; duodenum; fetus; intestine; paediatrics;
D O I
10.1046/j.1365-2125.2001.01370.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To investigate the effects of age and disease states on the expression and activity of intestinal CYP3A4 in a paediatric population. Methods Duodenal biopsies and surgical sections were collected from 104 paediatric patients (age range 2 weeks to 17 years) and from 11 foetuses. An S9 fraction was prepared in each case. CYP3A4 expression was assessed by Western blotting and by immunohistochemistry; activity was measured by the rate of formation of 6 beta -hydroxytestosterone from testosterone. Villin expression was used as a marker of enterocyte harvest to normalize CYP3A4 expression and activity data. Results In the 74 histologically normal paediatric biopsies there were statistically significant increases in CYP3A4 expression (r(2)=0.19, P=0.001) and activity (r(2)=0.17, P=0.02) with age. CYP3A4 was practically absent in fetal duodenum and was expressed at relatively low levels in neonates (P<0.05 between neonates and children >5 years). Active coeliac disease resulted in significant (P<0.001) decreases in CYP3A4 expression and activity. Conclusions Duodenal CYP3A4 is present at significantly lower levels in neonates and in patients with active coeliac disease. This may have clinical significance with respect to the oral bioavailability of CYP3A4 substrates.
引用
收藏
页码:451 / 460
页数:10
相关论文
共 45 条
[1]  
BISSET WM, 1998, FORFAR ARNEILS TXB P, P439
[2]   DEVELOPMENTAL PATTERN OF GLUCOSE-6-PHOSPHATASE ACTIVITY IN THE SMALL-INTESTINE OF THE MOUSE FETUS [J].
CALVERT, R ;
MALKA, D ;
MENARD, D .
HISTOCHEMISTRY, 1979, 63 (02) :209-220
[3]  
COONEY GF, 1994, TRANSPLANT P, V26, P2779
[4]   Cytochrome P450 3A - Ontogeny and drug disposition [J].
de Wildt, SN ;
Kearns, GL ;
Leeder, JS ;
van den Anker, JN .
CLINICAL PHARMACOKINETICS, 1999, 37 (06) :485-505
[5]  
EZZELL RM, 1989, DEVELOPMENT, V106, P407
[6]   Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers [J].
Fontana, RJ ;
Lown, KS ;
Paine, MF ;
Fortlage, L ;
Santella, RM ;
Felton, JS ;
Knize, MG ;
Greenberg, A ;
Watkins, PB .
GASTROENTEROLOGY, 1999, 117 (01) :89-98
[7]   THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE [J].
GOMEZ, DY ;
WACHER, VJ ;
TOMLANOVICH, SJ ;
HEBERT, MF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :15-19
[8]   The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin [J].
Gorski, JC ;
Jones, DR ;
Haehner-Daniels, BD ;
Hamman, MA ;
O'Mara, EM ;
Hall, SD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (02) :133-143
[9]   CHARACTERIZATION OF DEXTROMETHORPHAN N-DEMETHYLATION BY HUMAN LIVER-MICROSOMES - CONTRIBUTION OF THE CYTOCHROME-P450 3A (CYP3A) SUBFAMILY [J].
GORSKI, JC ;
JONES, DR ;
WRIGHTON, SA ;
HALL, SD .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (01) :173-182
[10]   DRUG ABSORPTION IN GASTROINTESTINAL-DISEASE AND SURGERY - CLINICAL PHARMACOKINETIC AND THERAPEUTIC IMPLICATIONS [J].
GUBBINS, PO ;
BERTCH, KE .
CLINICAL PHARMACOKINETICS, 1991, 21 (06) :431-447